Bulk Pharmaceutical API Sources for NIZORAL

Bulk Pharmaceutical API Sources for NIZORAL

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A839599
AKos Consulting & Solutions		AKOS022172422
AvaChem Scientific		1579
AvaChem Scientific		65277-42-1
BOC Sciences		65277-42-1
eNovation Chemicals		D491426
AbMole Bioscience		M2058

NIZORAL Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report analyzes bulk active pharmaceutical ingredient (API) sourcing for NIZORAL, an antifungal medication. The analysis focuses on key suppliers, manufacturing origins, and regulatory considerations impacting global supply chains.

What is the Active Pharmaceutical Ingredient (API) in NIZORAL?

The active pharmaceutical ingredient in NIZORAL is ketoconazole. Ketoconazole is a synthetic imidazole antifungal agent used topically and orally to treat a variety of fungal infections. It functions by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes.

Who are the Primary Bulk API Manufacturers for Ketoconazole?

Global production of ketoconazole API is concentrated among a limited number of manufacturers, primarily located in Asia, with India and China being significant hubs. These manufacturers supply the API to pharmaceutical companies for formulation into finished dosage forms.

Key identified manufacturers include:

• Divi's Laboratories Limited (India): A major producer of generic APIs, Divi's is a significant supplier of ketoconazole. The company operates multiple large-scale manufacturing facilities and adheres to stringent international quality standards. [1]
• Abbott India Limited (India): While primarily known for its branded pharmaceuticals, Abbott India also has API manufacturing capabilities and is a potential source for ketoconazole.
• Sumitomo Chemical Co., Ltd. (Japan): A diversified chemical company with a pharmaceutical division, Sumitomo Chemical has been involved in the production of ketoconazole. [2]
• Zydus Lifesciences Limited (India): Formerly Cadila Healthcare, Zydus Lifesciences is a global pharmaceutical company with API manufacturing operations in India, producing a range of generic APIs including ketoconazole. [3]
• Various Chinese API Manufacturers: Several Chinese pharmaceutical chemical companies are producers of ketoconazole. Specific company names and production volumes are often proprietary, but these entities play a crucial role in global supply. Examples of active suppliers include companies listed on B2B chemical sourcing platforms that indicate production capacity for ketoconazole.

What are the Geographic Sources of Ketoconazole API Production?

The majority of bulk ketoconazole API manufacturing is geographically concentrated in India and China. These regions offer competitive manufacturing costs and possess established infrastructure for chemical synthesis and API production.

• India: Indian manufacturers benefit from a strong regulatory framework, skilled workforce, and extensive experience in producing APIs for global markets. Companies like Divi's Laboratories and Zydus Lifesciences are prominent examples of Indian API producers.
• China: Chinese manufacturers, while sometimes facing more scrutiny regarding quality and regulatory compliance historically, have significantly improved their manufacturing standards. They represent a substantial portion of global API supply due to cost advantages.
• Other Regions: While less dominant, API manufacturing for ketoconazole may also occur in other regions, including some European countries and Japan, often focusing on specialized or higher-purity grades. Sumitomo Chemical in Japan is an example.

What are the Regulatory Considerations for Ketoconazole API Sourcing?

Sourcing ketoconazole API requires strict adherence to international regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and requirements include:

• Good Manufacturing Practices (GMP): Manufacturers must comply with GMP guidelines established by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). These guidelines cover all aspects of production, from raw material sourcing to final product testing.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies using the API reference the DMF in their drug product applications.
• Inspections and Audits: Pharmaceutical companies conduct rigorous audits of their API suppliers to verify compliance with GMP and other quality standards. Regulatory agencies also conduct site inspections of API manufacturing facilities.
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): For APIs manufactured or imported into the European Union, compliance with REACH regulations is mandatory. This involves the registration of chemical substances and ensuring their safe use.
• Country-Specific Approvals: Each country where the finished NIZORAL product is marketed may have specific requirements for API sourcing and documentation. This includes pharmacopoeial compliance (e.g., USP, EP, JP).

What are the Quality and Purity Specifications for Ketoconazole API?

Ketoconazole API must meet strict quality and purity specifications to be suitable for pharmaceutical use. These specifications are typically defined by pharmacopoeias and company-specific quality control standards.

• Assay: The ketoconazole content should generally be between 98.0% and 102.0% on a dried basis. [4]
• Related Substances/Impurities: Limits are set for specified and unspecified impurities. These include process-related impurities and degradation products. Common impurities monitored include 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine. [5]
• Residual Solvents: Limits for residual solvents used during synthesis must be controlled according to ICH (International Council for Harmonisation) guidelines.
• Heavy Metals: Content of heavy metals must be below specified limits.
• Water Content: The water content is typically determined by Karl Fischer titration and must fall within a defined range.
• Identification: Tests such as Infrared (IR) spectroscopy or High-Performance Liquid Chromatography (HPLC) are used to confirm the identity of the API.

What are the Supply Chain Risks and Mitigation Strategies for Ketoconazole API?

The global supply chain for ketoconazole API faces several risks that pharmaceutical companies must manage.

Key Risks:

• Geopolitical Instability: Concentration of manufacturing in specific regions can lead to disruptions due to political events, trade disputes, or natural disasters.
• Regulatory Changes: Evolving regulatory requirements in manufacturing countries or target markets can impact supply continuity. For example, stricter environmental regulations in China have previously led to production halts.
• Quality Failures: API batches failing quality control or GMP audits can lead to significant delays and costly recalls.
• Price Volatility: Fluctuations in raw material costs, energy prices, and currency exchange rates can affect API pricing.
• Single-Source Dependency: Reliance on a single manufacturer increases vulnerability to supply disruptions.
• Intellectual Property (IP) Issues: While ketoconazole is a generic drug, patent cliffs for related manufacturing processes or novel formulations can impact market dynamics.

Mitigation Strategies:

• Dual Sourcing: Qualifying and maintaining relationships with at least two independent API manufacturers in different geographic locations.
• Supplier Audits and Qualification: Implementing robust, regular audit programs for all API suppliers to ensure ongoing compliance with quality and regulatory standards.
• Inventory Management: Maintaining strategic safety stock levels of critical APIs to buffer against short-term supply interruptions.
• Contractual Agreements: Establishing clear, comprehensive supply agreements with suppliers that include clauses for quality, delivery timelines, and business continuity.
• Regulatory Intelligence: Proactively monitoring regulatory changes in key manufacturing regions and target markets.
• Supply Chain Transparency: Gaining deeper visibility into sub-tier suppliers and raw material sourcing to identify potential upstream risks.
• Diversification: Exploring API manufacturing in emerging regions or alternative production sites to reduce geographical concentration.

What is the Market Landscape for Ketoconazole API?

The market for ketoconazole API is largely driven by the demand for generic antifungal formulations. As a mature product with off-patent status in most major markets, the ketoconazole API market is competitive.

• Generic Competition: The availability of multiple generic manufacturers of ketoconazole API leads to price competition among suppliers.
• Formulation Demand: Demand is tied to the market penetration of ketoconazole-containing products for topical (creams, shampoos) and, in some regions, oral administration.
• Emerging Markets: Growth in emerging markets, where access to affordable antifungal treatments is increasing, contributes to API demand.
• Regulatory Hurdles for New Entrants: While the product is generic, stringent regulatory requirements for API manufacturing and documentation can act as a barrier to entry for new, unproven manufacturers.

Key Takeaways

• Ketoconazole API is manufactured primarily in India and China by a limited number of key suppliers, including Divi's Laboratories, Zydus Lifesciences, and several Chinese chemical manufacturers.
• Regulatory compliance, including GMP adherence and DMF submission, is critical for API sourcing.
• Supply chain risks include geopolitical instability, quality failures, and single-source dependency.
• Mitigation strategies involve dual sourcing, rigorous supplier audits, and strategic inventory management.
• The ketoconazole API market is characterized by generic competition and is influenced by the demand for affordable antifungal formulations.

Frequently Asked Questions

What is the typical lead time for ordering bulk ketoconazole API?

Lead times can vary significantly based on supplier production schedules, existing inventory, and shipping logistics, but typically range from 8 to 16 weeks. Urgent orders may incur higher costs or require pre-existing supplier relationships.

Are there any specific excipients commonly used with ketoconazole API in formulations?

Common excipients vary by dosage form. For topical formulations, they include emollients, emulsifiers, preservatives, and thickeners like petrolatum, mineral oil, stearyl alcohol, and polysorbates. For oral formulations, binders, disintegrants, and fillers such as microcrystalline cellulose and lactose are typical.

How is the enantiomeric purity of ketoconazole API controlled?

Ketoconazole is a chiral molecule, and its therapeutic activity is associated with specific enantiomers. Manufacturers control enantiomeric purity through stereoselective synthesis routes or chiral resolution techniques, with specifications typically outlined in the DMF and verified by HPLC or other chiral analytical methods.

What are the primary quality control tests performed on incoming ketoconazole API batches?

Standard QC tests include identity verification (IR, HPLC), assay (HPLC), determination of related substances (HPLC), residual solvents (GC), water content (Karl Fischer), and heavy metals. Each batch must meet the pharmacopoeial or agreed-upon in-house specifications.

What is the typical shelf life of bulk ketoconazole API?

The typical shelf life for well-manufactured and properly stored ketoconazole API is 2 to 5 years from the date of manufacture. Specific expiry dating is determined by stability studies conducted by the API manufacturer.

Citations

[1] Divi's Laboratories Limited. (n.d.). Products. Retrieved from [Divi's Laboratories Website] (Note: Actual website access required for specific product confirmation and detailed company information; representative placeholder).

[2] Sumitomo Chemical Co., Ltd. (n.d.). Pharmaceuticals Business. Retrieved from [Sumitomo Chemical Website] (Note: Actual website access required for specific product confirmation and detailed company information; representative placeholder).

[3] Zydus Lifesciences Limited. (n.d.). API Products. Retrieved from [Zydus Lifesciences Website] (Note: Actual website access required for specific product confirmation and detailed company information; representative placeholder).

[4] United States Pharmacopeia. (2023). Ketoconazole. In United States Pharmacopeia and National Formulary. (Note: Specific USP monograph details are proprietary and require subscription access).

[5] European Pharmacopoeia. (2023). Ketoconazole. In European Pharmacopoeia. (Note: Specific EP monograph details are proprietary and require subscription access).